<DOC>
	<DOCNO>NCT00378209</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness side effect bortezomib , lenalidomide dexamethasone combination relapse relapsed refractory multiple myeloma . Each drug approve U.S Food Drug Administration , approve combination treat patient set .</brief_summary>
	<brief_title>Bortezomib , Lenalidomide , Dexamethasone Combination Therapy Patients With Relapsed Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>- Participants take study medication clinic Cycle 1 day 1 . Each treatment cycle last three week . They take lenalidomide ( capsule ) every day first two week ( day 1-14 ) . They take dexamethasone ( tablet ) Day 1 , 2 , 4 , 5 , 8 , 9 , 11 12 come outpatient treatment center intravenous bortezomib Day 1 , 4 , 8 11 . The third week cycle rest period participant take study medication . - Certain test procedure perform throughout treatment cycle definitive time period . These test include : medical history update , physical/neurological examination , skeletal survey ( x-rays scan ) , blood sample , urine sample , optional bone marrow aspiration/tissue biopsy , 12-lead ECG , MRI/CT ( need ) . - It expect participant go complete least 8 cycle study , add 168 day . If participant complete first 8 cycle , stable respond disease experience bad side effect , allow continue treatment maintenance schedule , detail protocol , study doctor 's discretion .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis multiple myeloma base standard diagnostic criterion new International Myeloma Foundation 2003 Diagnostic Criteria Relapsed relapsed refractory disease receive 1 3 prior regimen Negative serum urine pregnancy test Age 18 year old Karnofsky performance status 60 great Grade 2 great peripheral neuropathy within 14 day enrollment Renal insufficiency ( serum creatinine &gt; 2.5 mg/dL ) Evidence mucosal internal bleeding and/or platelet refractory ANC &lt; 1000 cells/mm3 Hemoglobin &lt; 8.0 g/dL AST ALT great equal 2 x ULN Concomitant therapy medication include corticosteroid Myocardial infarction within 6 month prior enrollment NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Clinically relevant active infection serious comorbid medical condition Prior malignancy ( within last 3 year ) except adequately treat basal cell squamous cell skin cancer , situ cervical breast cancer , situ prostate cancer Pregnant breastfeed Serious medical psychiatric illness likely interfere participation clinical study . Uncontrolled diabetes mellitus Hypersensitivity acyclovir similar antiviral drug POEMS syndrome Known HIV infection Known active hepatitis B C viral infection Known intolerance steroid therapy Subjects primary refractory disease , define progression initial treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>relapse multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>